This clinical trial is focused on studying a condition known as venous thromboembolism (VTE), which is a type of blood clot that can occur in patients with certain types of cancer, specifically gastrointestinal (GI) and genitourinary (GU) cancer. The study is comparing two treatments: Abelacimab, a new medication given as a solution for infusion, and Fragmin® (dalteparin sodium), a solution for injection that is already used to treat VTE. The purpose of the study is to see if Abelacimab is as effective as Fragmin® in preventing the recurrence of VTE in these patients.

Participants in the study will receive either Abelacimab or Fragmin® for a period of six months. The study is designed to monitor the recurrence of VTE and any bleeding events during this time. Abelacimab is administered through a method called subcutaneous use, which means it is injected under the skin. Similarly, Fragmin® is also given through subcutaneous injection. The study aims to determine if Abelacimab can prevent VTE recurrence as effectively as Fragmin® and, if successful, to see if it might be even better.

Throughout the study, participants will be closely monitored to track any occurrences of VTE and to ensure their safety. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. However, the evaluation of the study’s outcomes is blinded, meaning that the people assessing the results do not know which treatment the participants received, to ensure unbiased results. The study is expected to continue until 2025, providing valuable information on the effectiveness of Abelacimab in treating VTE in patients with GI or GU cancer.